Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Syneos Health (NASDAQ:SYNH) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,975 shares of the company’s stock, valued at approximately $141,000.
Other institutional investors also recently made changes to their positions in the company. Globeflex Capital L P purchased a new position in Syneos Health during the fourth quarter worth approximately $210,000. Public Employees Retirement Association of Colorado purchased a new stake in Syneos Health in the first quarter valued at $234,000. Advantus Capital Management Inc purchased a new stake in Syneos Health in the first quarter valued at $243,000. Dupont Capital Management Corp purchased a new stake in Syneos Health in the first quarter valued at $355,000. Finally, SG Americas Securities LLC purchased a new stake in Syneos Health in the first quarter valued at $599,000.
SYNH stock opened at $40.95 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $4.15 billion, a P/E ratio of 21.11, a PEG ratio of 0.98 and a beta of 0.79. Syneos Health has a 12-month low of $31.10 and a 12-month high of $61.10.
Syneos Health (NASDAQ:SYNH) last posted its quarterly earnings data on Wednesday, May 9th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.04. The firm had revenue of $761.00 million for the quarter, compared to the consensus estimate of $767.24 million. Syneos Health had a positive return on equity of 8.79% and a negative net margin of 5.50%. The business’s quarterly revenue was up 201.9% compared to the same quarter last year. research analysts expect that Syneos Health will post 2.36 EPS for the current year.
SYNH has been the topic of a number of research analyst reports. ValuEngine downgraded Syneos Health from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd. KeyCorp restated an “overweight” rating and issued a $46.00 target price (down previously from $50.00) on shares of Syneos Health in a research report on Monday, February 26th. SunTrust Banks lifted their target price on Syneos Health to $55.00 and gave the company a “buy” rating in a research report on Thursday, March 1st. Wells Fargo upgraded Syneos Health from a “market perform” rating to an “outperform” rating in a research report on Friday, February 23rd. Finally, Zacks Investment Research upgraded Syneos Health from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $50.40.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.